Accueil >
Publications >
Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era

20 août 2018Journal of Clinical Oncology

DOI : 10.1200/jco.2017.77.4174

Auteurs

Harmke J. Groot, Sjoukje Lubberts, Ronald de Wit, Johannes A. Witjes, Jan Martijn Kerst, Igle J. de Jong, Gerard Groenewegen, Alfons J.M. van den Eertwegh, Philip M. Poortmans, Heinz-Josef Klümpen, Hetty A. van den Berg, Tineke J. Smilde, Ben G.L. Vanneste, Maureen J. Aarts, Luca Incrocci, Alfons C.M. van den Bergh, Katarzyna Jóźwiak, Alexandra W. van den Belt-Dusebout, Simon Horenblas, Jourik A. Gietema, Flora E. van Leeuwen, Michael Schaapveld

Résumé

Purpose

Testicular cancer (TC) treatment increases risk of subsequent malignant neoplasms (SMNs). It is unknown whether changes in TC treatment over time have affected SMN risk.

Methods

Solid SMN risk was evaluated in a multicenter cohort comprising 5,848 1-year survivors treated for TC before age 50 years between 1976 and 2007. SMN incidence was compared with cancer incidence in the general population. Treatment-specific risks were assessed using multivariable regression in a case-cohort design.

Results

After a median follow-up of 14.1 years, 350 solid SMNs were observed, translating into a 1.8-fold (95% CI, 1.6-2.0) increased risk compared with general population rates. Solid SMN risk was increased in patients with seminoma and those with nonseminoma (standardized incidence ratio, 1.52 and 2.21, respectively). Patients with nonseminoma experienced increased risk of SMNs of the thyroid, lung, stomach, pancreas, colon, and bladder and of melanoma and soft tissue sarcoma, whereas those with seminoma experienced increased risk of SMNs of the small intestine, pancreas, and urinary bladder. The 25-year cumulative incidence of solid SMNs was 10.3% (95% CI, 9.0% to 11.6%). In multivariable analysis, platinum-based chemotherapy was associated with increased risk of a solid SMN (hazard ratio [HR], 2.40; 95% CI, 1.58 to 3.62), colorectal SMN (HR, 3.85; 95% CI, 1.67 to 8.92), and noncolorectal GI SMN (HR, 5.00; 95% CI, 2.28 to 10.95). Receipt of platinum 400 to 499 and ≥ 500 mg/m2 increased solid SMN risk compared with surgery only (HR, 2.43; 95% CI, 1.40 to 4.23 and HR, 2.42; 95% CI, 1.50 to 3.90, respectively), whereas risk was not significantly increased with lower doses (HR, 1.75; 95% CI, 0.90 to 3.43). The HR of a GI SMN increased by 53% (95% CI, 26% to 80%) per 100 mg/m2 of platinum-containing chemotherapy. The HR of an infradiaphragmatic SMN increased by 8% per Gray of radiation dose administered (95% CI, 6% to 9%; P < .001).

Conclusion

Radiotherapy and platinum-containing chemotherapy are associated with increased solid SMN risk, specifically with GI SMNs.